Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG

Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG

Background: Women with hormone-responsive breast cancer who receive adjuvant endocrine treatment with aromatase inhibitors (AI) are known to be at higher fracture risk due to a marked increase in bone resorption. In 2017, several interdisciplinary cancer and bone societies involved in the management...

Full description

Saved in:
Bibliographic Details
Main Authors: Peyman Hadji, Matty Aapro, Nasser Al-Dagri, Majed Alokail, Emmanuel Biver, Jean-Jacques Body, Maria Luisa Brandi, Janet Brown, Cyrille Confavreux, Bernard Cortet, Matthew Drake, Peter Ebeling, Erik Fink Eriksen, Ghada El-Hajj Fuleihan, Theresa A. Guise, Nick C. Harvey, Andreas Kurth, Bente Langdahl, Willem Lems, Radmila Matijevic, Eugene McCloskey, Rossella Nappi, Santiago Palacios, Georg Pfeiler, Jean-Yves Reginster, René Rizzoli, Daniele Santini, Sansin Tuzun, Catherine Van Poznak, Tobias De Villiers, M. Carola Zillikens, Robert Coleman
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:Journal of Bone Oncology
Subjects:
Breast cancer
Osteoporosis
Aromatase Inhibitor
Fracture
Bisphosphonate
Denosumab
Online Access:http://www.sciencedirect.com/science/article/pii/S2212137425000351
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S2212137425000351

Similar Items